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Abstract
In this chapter, we review how HDL is generated, remodeled, and catabolized in
plasma. We describe key features of the proteins that participate in these
processes, emphasizing how mutations in apolipoprotein A-I (apoA-I) and the
other proteins affect HDL metabolism.
The biogenesis of HDL initially requires functional interaction of apoA-I
with the ATP-binding cassette transporter A1 (ABCA1) and subsequently
interactions of the lipidated apoA-I forms with lecithin/cholesterol
acyltransferase (LCAT). Mutations in these proteins either prevent or impair
the formation and possibly the functionality of HDL.
Remodeling and catabolism of HDL is the result of interactions of HDL with
cell receptors and other membrane and plasma proteins including hepatic lipase
(HL), endothelial lipase (EL), phospholipid transfer protein (PLTP), cholesteryl
ester transfer protein (CETP), apolipoprotein M (apoM), scavenger receptor
class B type I (SR-BI), ATP-binding cassette transporter G1 (ABCG1), the F1
subunit of ATPase (Ecto F1-ATPase), and the cubulin/megalin receptor.
Similarly to apoA-I, apolipoprotein E and apolipoprotein A-IV were shown to
form discrete HDL particles containing these apolipoproteins which may have
important but still unexplored functions. Furthermore, several plasma proteins
were found associated with HDL and may modulate its biological functions. The
effect of these proteins on the functionality of HDL is the topic of ongoing
research.
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1 Biogenesis of HDL
The biogenesis of HDL is a complex process and involves several membrane bound
and plasma proteins (Zannis et al. 2004a). The first step in HDL biogenesis involves
secretion of apoA-I mainly by the liver and the intestine (Zannis et al. 1985).
Secreted apoA-I interacts functionally with ABCA1, and this interaction leads to
the transfer of cellular phospholipids and cholesterol to lipid-poor apoA-I. The
lipidated apoA-I is gradually converted to discoidal particles enriched in
unesterified cholesterol. The esterification of free cholesterol by the enzyme leci-
thin/cholesterol acyltransferase (LCAT) (Zannis et al. 2006a) converts the discoidal
to spherical HDL particles (Fig. 1).
The absence or inactivating mutations in apoA-I, ABCA1, and LCAT prevent
the formation of apoA-I-containing HDL (Daniil et al. 2011). For this reason, we
classify the apoA-I, ABCA1, and LCAT interactions that will be discussed in this
chapter as early steps in the biogenesis of HDL. Following a similar pathway, apoE
and apoA-IV can also synthesize HDL particles that contain these proteins (Duka
et al. 2013; Kypreos and Zannis 2007). The first part of this review provides
important information on the unique properties of apoA-I that permits it to acquire
lipids via interactions with ABCA1 and LCAT. It also provides examples of how
specific mutations in apoA-I disrupt specific steps in the pathway of HDL biogene-
sis and generate distinct aberrant HDL phenotypes. The HDL phenotypes described
here can serve as molecular markers that could be used for the diagnosis, prognosis,
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and potential treatment of HDL abnormalities or dyslipidemias associated
with HDL.
1.1 ATP-Binding Cassette Transporter A1 (ABCA1)
1.1.1 Structure of apoA-I and Its Interactions with ABCA1 In Vitro
apoA-I contains 22 or 11 amino acid repeats which, according to the models of
Nolte and Atkinson (1992), are organized in amphipathic a-helices (Segrest
et al. 1974). Based on the crystal structure of apoA-I in solution (Borhani
et al. 1997, 1999), a belt model was proposed to explain the structure of apoA-I
on discoidal HDL particles (Segrest et al. 1999). Various models have been
proposed to explain the arrangement of apoA-I on spherical HDL particles based
on structural work and cross-linking(Wu et al. 2011; Silva et al. 2008; Huang
et al. 2011). Details on the structure of apoA-I and HDL are provided in chapter
“Structure of HDL: Particle Subclasses and Molecular Components.”
ABCA1 is a ubiquitous protein that belongs to the ABC family of transporters
and is expressed abundantly in the liver, macrophages, brain, and various other
tissues (Langmann et al. 1999; Kielar et al. 2001). ABCA1 is localized only on the
basolateral surface of the hepatocytes (Neufeld et al. 2002); it is also found on
endocytic vesicles and was shown to travel between late endocytic vesicles and the
cell surface (Neufeld et al. 2001). ABCA1 promotes efflux of cellular phospholipids
Fig. 1 Schematic representation of the pathway of the biogenesis of HDL containing apoA-I or
apoE or apoA-IV
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and cholesterol to lipid-free or minimally lipidated apoA-I and other
apolipoproteins, but not to spherical HDL particles (Wang et al. 2000; Remaley
et al. 2001).
Studies in HeLa cells that expressed an ABCA1 green fluorescence fusion
protein showed the intracellular trafficking of ABCA1 complexed to apoA-I
(Neufeld et al. 2001, 2002). Other studies showed that in macrophages ABCA1
associates with apoA-I in the coated pits, is internalized, interacts with intracellular
lipid pools, and is re-secreted as a lipidated particle (Takahashi and Smith 1999;
Smith et al. 2002; Lorenzi et al. 2008). A similar pathway that leads to transcytosis
has been described in endothelial cells (Cavelier et al. 2006; Ohnsorg et al. 2011).
A series of cell culture and in vitro experiments investigated the ability of apoA-
I mutants to promote ABCA1-mediated efflux of cholesterol and phospholipids and
to cross-link to ABCA1. These mutants had amino-terminal deletions, carboxy-
terminal deletions that removed the 220-231 region, carboxy-terminal deletions that
maintained the 220-231 region, and double deletions of the amino- and carboxy-
terminal regions (Chroni et al. 2003).
These studies presented in Chroni et al. (2003) showed that wild-type (WT) -
ABCA1-mediated cholesterol and phospholipid efflux was not affected by amino-
terminal apoA-I deletions, but it was diminished by carboxy-terminal deletions in
which residues 220-231 were removed. Efflux was not affected by deletion of the
carboxy-terminal 232-243 region, and it was restored to 80 % of WT control by
double deletions of both the amino- and carboxy-termini (Zannis et al. 2004a,
2006a; Chroni et al. 2003; Reardon et al. 2001). Lipid efflux was either unaffected
or moderately reduced by a variety of point mutations or deletions of internal
helices 2–7. The findings indicated that different combinations of central helices
can promote lipid efflux (Chroni et al. 2004a, b). Chemical cross-linking/
immunoprecipitation studies showed that the ability of apoA-I mutants to promote
ABCA1-depended lipid efflux is correlated with the ability of these mutants to be
cross-linked efficiently to ABCA1 (Chroni et al. 2004b). Cross-linking between
apoA-I and ABCA1 and cholesterol efflux was also affected by mutations in
ABCA1 that are found in patients with Tangier disease. The majority of the
ABCA1 mutants cross-link poorly to WT apoA-I and have diminished capacity to
promote cholesterol efflux (Bodzioch et al. 1999; Fitzgerald et al. 2002). A notable
exemption is the ABCA1[W590S] mutant which cross-linked stronger to apoA-I
than to WT ABCA1 but had diminished capacity to promote cholesterol efflux and
to promote formation of HDL (Bodzioch et al. 1999; Fitzgerald et al. 2001, 2002).
We suggested that this ABCA1 mutation may have altered the environment of the
binding site of ABCA1 in such a way that the binding of apoA-I is strong but not
productive and thus prevented efficient lipid efflux (Chroni et al. 2004b).
1.1.2 Interaction of apoA-I with ABCA1 In Vivo Initiates
the Biogenesis of HDL
Inactivating mutations in ABCA1 found in patients with Tangier disease are
associated with very low levels of total plasma and HDL cholesterol, diminished
capacity to promote cholesterol efflux, formation of preβ-migrating particles, and
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abnormal lipid deposition in various tissues (Daniil et al. 2011; Brunham
et al. 2006b; Orso et al. 2000; Assmann et al. 2001; Timmins et al. 2005).
Analysis of the serum of carriers with ABCA1 mutations by two-dimensional
gel electrophoresis and western blotting using a rabbit polyclonal anti-human
apoA-I antibody showed that subjects homozygous or compound mutant hetero-
zygous for ABCA1 fail to form α-HDL particles, but instead they form preβ- and
other small-size particles (Fig. 2).
As explained later, such particles are found in the plasma of mice expressing
C-terminal mutants and may be created by mechanisms that involve nonproductive
interactions between ABCA1 and apoA-I (Chroni et al. 2007; Fotakis et al. 2013a).
Several ABCA1 mutations in humans that alter the functions of ABCA1 are
associated with increased susceptibility to atherosclerosis (Singaraja et al. 2003).
Specific amino-acid substitutions found in the Danish general population were
associated with increased risk for ischemic heart disease and reduced life expec-
tancy through unknown mechanisms (Frikke-Schmidt et al. 2008). Inactivation of
the ABCA1 gene in mice leads to low total serum cholesterol levels, lipid deposi-
tion in various tissues, impaired growth, and neuronal development and mimics the
phenotype described for patients with Tangier disease (Orso et al. 2000). In addition
ABCA1-deficient mice exhibit moderate increase in cholesterol absorption in
response to high cholesterol diet (McNeish et al. 2000; Aiello et al. 2002). The
role of ABCA1 on the lipid content of bile salts and cholesterol secretion is not clear
(Vaisman et al. 2001; Groen et al. 2001).
Bone marrow transplantation experiments indicated that ABCA1 plays an
important role in the control of macrophage recruitment to the tissues (Van Eck
et al. 2002, 2006).
The contribution of ABCA1 in the pathogenesis of atherosclerosis in mice is
presented in chapter “Mouse Models of Disturbed HDL Metabolism” (Hoesha and
Van Eck). In men and mice, the majority of HDL is produced by the liver (Brunham
et al. 2006a). When the liver and intestinal ABCA1 genes were inactivated in mice,
Fig. 2 Two-dimensional gel electrophoresis of plasma obtained from homozygotes or compound
heterozygotes ABCA1-deficient human subjects with Tangier disease as indicated [Adapted from
Daniil et al. (2011)]
HDL Biogenesis, Remodeling, and Catabolism 59
HDL was not found in plasma, indicating that the liver and the intestine are the only
sites that contribute to the production of HDL (Timmins et al. 2005). Following
intestinal-specific inactivation of the ABCA1 gene in mice, the HDL that was
generated by the liver accounted for 70 % of the HDL found in WT mice (Brunham
et al. 2006a). In mice that do not express hepatic ABCA1, the HDL concentration in
the lymph was greatly diminished despite the fact that the intestine contributes 30 %
to the synthesis of HDL. This implies that the HDL that is produced in the intestine
is secreted directly into the plasma (Brunham et al. 2006a). This is further supported
by the finding that in mice that do not express intestinal ABCA1, the apoA-I and
cholesterol concentration of lymph was not affected (Brunham et al. 2006a).
In liver-specific or whole-body ABCA1 knockout mice, the plasma HDL cata-
bolism and the fractional catabolic rate of HDL by the liver and to a lesser extent by
the kidney and the adrenal is increased (Timmins et al. 2005; Singaraja et al. 2006).
In ABCA1-deficient mice, lipidated apoA-I particles or preβ-HDL failed to mature
and are rapidly catabolized by the kidney (Timmins et al. 2005).
1.1.3 Unique Mutations in apoA-I May Affect apoA-I/ABCA1
Interactions and Inhibit the First Step in the Pathway of HDL
Biogenesis
The in vivo interactions of apoA-I with ABCA1 were studied systematically by
adenovirus-mediated gene transfer of WT and mutant apoA-I forms. Similar studies
were performed to probe the interactions of lipid-bound apoA-I with LCAT. Four to
five days postinfection plasma was collected and analyzed for lipids and lipoproteins
and by two-dimensional gel electrophoresis to identify the HDL subpopulations. The
plasma was fractionated by density gradient ultracentrifugation and fast protein liquid
chromatography (FPLC), and the HDL fraction was analyzed by electron microscopy
(EM) to assess the size and shape of HDL (Chroni et al. 2003; Reardon et al. 2001).
Also the hepatic mRNA levels of apoA-I were determined to ensure that there was
comparable expression of the WT and the mutant apoA-I forms (Zannis et al. 2004a;
Chroni et al. 2003, 2007; Reardon et al. 2001).
We have studied most recently the effect of two sets of point mutations in the
218-222 and 225-230 region of apoA-I that affects apoA-I/ABCA1 interactions on
the biogenesis of HDL. Adenovirus-mediated gene transfer of these mutants in
apoA-I/ x apoE/ mice (Fotakis et al. 2013a, b) showed that compared to the
WT apoA-I, the expression of an apoA-I[L218A/L219A/V221A/L222A] mutant
decreased plasma cholesterol, apoA-I, and HDL cholesterol levels and generated
preβ- and α4 HDL subpopulations (Fotakis et al. 2013a) (Table 1 and Fig. 3a–g).
To eliminate the involvement of apoE in the generation of apoE-containing HDL
particles (Kypreos and Zannis 2007), the apoA-I[L218A/L219A/V221A/L222A]
mutant was expressed in apoA-I/ x apoE/ mice via adenovirus-mediated gene
transfer (Fotakis et al. 2013a). In this mouse background, the FPLC fractionation of
the plasma showed the near absence of an HDL cholesterol peak. Density gradient
ultracentrifugation of the plasma showed small amount of the apoA-I in HDL3 and
in d< 1.21 g/ml fractions (Fig. 3a). EM analysis showed the presence of discoidal
particles along with larger particles corresponding in size to IDL/LDL (Fig. 3b).
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Table 1 Plasma lipids and hepatic mRNA levels of apoA-I/ or apoA-I/ x apoE/ mice















WT apoA-I in apoA-I/ mice 278 74 78 24 100 26 260 40
apoA-I[L218A/L219A/V221A/
L222A] in apoA-I/ mice
45 14 50 20 95 24 41 5
WT apoA-I in apoA-I/ x
apoE/ mice
1,343 104 294 129 100 13 –
apoA-I[L218A/L219A/V221A/
L222A] in apoA-I/ x apoE/
mice
778 52 18 2 92 23 –
apoA-I[L218A/L219A/V221A/
L222A] plus LCAT in apoA-I/
x apoE/ mice
754 122 37 10 90 3 –
Fig. 3 (a–g) ApoA-I mutations and their effect on the HDL phenotypes. Analysis of plasma of
apoA-I/ x apoE/ mice infected with adenoviruses expressing the WT apoA-I or the apoA-I
[L218A/L219A/V221A/L222A] mutant, as indicated, by density gradient ultracentrifugation and
SDS-PAGE (a, e). EM analysis of HDL fractions 6–7 obtained from apoA-I/ x apoE/ mice
expressing the WT apoA-I or the apoA-I[L218A/L219A/V221A/L222A] mutant, as indicated,
following density gradient ultracentrifugation of plasma (b, f). SDS gel electrophoresis showing
apoprotein composition of fractions 6 and 7 (c) used for the EM analysis in panel b.
Two-dimensional gel electrophoresis of plasma of apoA-I/ x apoE/ mice infected with
adenoviruses expressing WT apoA-I or the apoA-I[L218A/L219A/V221A/L222A] mutant, as
indicated (d, g)
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These particles may originate from apoB-48 containing lipoproteins that are found
in the HDL fractions (Fig. 3c). Two-dimensional gel electrophoresis showed the
presence of only preβ-HDL particles (Fig. 3d). Control experiments showed that
WT apoA-I when expressed in apoA-I/ x apoE/mice floated predominantly in
the HDL2/HDL3 region and generated spherical particles and normal preβ- and
α-HDL subpopulation (Fig. 3e–g).
Co-expression of the apoA-I[L218A/L219A/V221A/L222A] mutant and human
LCAT in apoA-I/ x apoE/ mice did not correct the plasma apoA-I levels and
did not correct the aberrant HDL phenotype.
The findings shed light to previous studies which showed that carboxy-terminal
deletion mutants that lacked the 220-231 region of apoA-I prevented the biogenesis
of normal α-HDL particles but allowed the formation of preβ-HDL particles
(Chroni et al. 2003, 2007).
Studies discussed in a later section showed that naturally occurring point
mutations in apoA-I when expressed in mouse models activate LCAT insufficiently
and in some instances lead to the accumulation of discoidal HDL particles in
plasma (Koukos et al. 2007a, b; Chroni et al. 2005a). A characteristic feature of
these mutations is that they could be corrected in vivo by the co-expression of the
mutant apoA-I and LCAT.
The phenotype produced by the apoA-I[L218A/L219A/V221A/L222A]
mutations is distinct from all previously described phenotypes and cannot be
corrected by overexpression of LCAT. In addition, the mutant protein had reduced
capability to promote the ABCA1-mediated cholesterol efflux. Although other
interpretations are possible, the in vivo and in vitro data suggest that the interaction
of the apoA-I [L218A/L219A/V221A/L222A] mutant with ABCA1 results in
defective lipidation of apoA-I that leads to the generation of preβ-HDL particles
that are not a good substrate for LCAT. If this interpretation is correct, the normal
lipidation of apoA-I may require a precise initial orientation of the apoA-I ligand
within the binding site of ABCA1 that is similar to that described for enzyme-
substrate interactions. Such a configuration would allow correct lipidation of apoA-
I that could subsequently undergo cholesterol esterification and formation of mature
HDL, whereas incorrectly lipidated apoA-I becomes a poor substrate for LCAT.
In addition to the unique role of the L218/L219/V221/L222 residues in the
biogenesis of HDL, the same residues are also required to confer trans-endothelial
transport capacity (Ohnsorg et al. 2011) and bactericidal activity (Biedzka-Sarek
et al. 2011) to apoA-I. These overall properties suggest that the L218/L219/V221/
L222 residues represent an effector domain for several activities of apoA-I.
The phenotype generated by the expression of the apoA-I[F225A/V227A/
F229A/L230A] mutant was similar to that obtained with the apoA-I[L218A/
L219A/V221A/L222A] mutant. However co-expression of the apoA-I[F225A/
V227A/F229A/L230A] mutant and human LCAT corrected the abnormal HDL
levels, created normal preβ- and α-HDL subpopulations, and generated spherical
HDL particles (Fotakis et al. 2013b).
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1.2 Lecithin/Cholesterol Acyltransferase (LCAT)
1.2.1 Interactions of Lipid-Bound ApoA-I with LCAT
Plasma LCAT is a 416 amino acid long plasma protein that is synthesized and
secreted primarily by the liver and to a much lesser extent by the brain and the testis
(Warden et al. 1989; Simon and Boyer 1970). LCAT interacts with discoidal and
spherical HDL and catalyzes the transfer of the 2-acyl group of lecithin or
phosphatidylethanolamine to the free hydroxyl residue of cholesterol to form
cholesteryl ester, using apoA-I as an activator (Fielding et al. 1972; Zannis
et al. 2004b). It also catalyzes the reverse reaction of esterification of lysolecithin
to lecithin (Subbaiah et al. 1980). The esterification of free cholesterol of HDL
in vivo converts the discoidal to mature spherical HDL particles (Jonas 2000;
Chroni et al. 2005a). Regarding the mechanism of activation of LCAT by apoA-I,
it has been proposed that residues R130 and K133 play an important role in the
formation of an amphipathic presentation tunnel located between helices 5-5 in the
double belt model. Such a tunnel could allow migration of the hydrophobic acyl
chains of phospholipids and the amphipathic unesterified cholesterol from the
bilayer to the active site of LCAT that contains sites for phospholipase activity
and esterification activity (Jones et al. 2009). The esterification of the cholesterol
converts the 3.67 residues per turn helices to an idealized 3.6 residues per turn helix
(Borhani et al. 1997).
Mutations in LCAT are associated with two phenotypes. The familial LCAT
deficiency (FLD) is characterized by the inability of the mutant LCAT to esterify
cholesterol on HDL and LDL and the accumulation of discoidal HDL in the plasma.
The fish eye disease (FED) is characterized by the inability of mutant LCAT to
esterify cholesterol on HDL only. Both diseases are characterized by low HDL
levels (Santamarina-Fojo et al. 2001) and formation of preβ- and α4
subpopulations.
Analysis of plasma of patients with complete LCAT deficiency (homozygous or
compound heterozygous carriers of functional LCAT mutations) by
two-dimensional electrophoresis shows mostly the presence of small α-HDL sub-
population (Daniil et al. 2011) (Fig. 4a, b). Analysis of plasma of LCAT-deficient
mice by two-dimensional electrophoresis shows the presence of preβ- and small-
size α4 HDL particles (Fig. 4c). Expression of human LCAT by adenovirus-
mediated gene transfer generated large-size α-HDL subpopulations (Fig. 4d). In
contrast, expression of a LCAT mutant generated preβ-HDL along with small-size
α4, α3, and α2 HDL subpopulations (Fig. 4e).
Sera obtained from LCAT heterozygotes had increased capacity to promote
ABCA1-mediated cholesterol efflux and decreased capacity to promote ABCG1-
and SR-BI-mediated cholesterol efflux from macrophages as compared with sera
obtained from normal subjects. These properties were attributed to the increased
preβ- and decreased α-HDL subpopulations in the sera of the LCAT heterozygotes
(Calabresi et al. 2009b). Heterozygosity for LCAT mutations in the Italian popu-
lation was not associated with increased preclinical atherosclerosis (Calabresi
et al. 2009a).
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The LCAT activation ability of apoA-I is inhibited following treatment with
MPO (Shao et al. 2008). In addition myeloperoxidase modification alters several
functions of HDL and generates pro-inflammatory HDL particles (Undurti
et al. 2009).
1.2.2 ApoA-I Mutations that Affect apoA-I/LCAT Interactions
Several naturally occurring apoA-I mutations that produce pathological phenotypes
have been described (Zannis et al. 2006b; Sorci-Thomas and Thomas 2002;
Miettinen et al. 1997b). It has been estimated that structural mutations of apoA-I
occur in 0.3 % of the Japanese population and may affect the plasma HDL levels
(Yamakawa-Kobayashi et al. 1999). From a total of 46 natural mutations of apoA-I,
25 are associated with low HDL levels, and 17 of these mutants reduce the capacity
of apoA-I to activate LCAT (Sorci-Thomas and Thomas 2002; Zannis et al. 2006b).
These mutations are clustered predominantly in or at the vicinity of helix 6 of apoA-I
and some of them predispose to atherosclerosis (Huang et al. 1998; Miller et al. 1998;
Miettinen et al. 1997b; Miccoli et al. 1996). Here we describe how some represen-
tative mutations of this category affect the biogenesis and maturation of HDL.
Fig. 4 (a–e) Two-dimensional gel electrophoresis from plasma obtained from one homozygote
and one compound heterozygote for LCAT deficiency as indicated (a, b) (Daniil et al. 2011).
Two-dimensional gel electrophoresis of plasma obtained from plasma of control LCAT/ mice
(a) and LCAT/mice infected with an adenovirus expressing either the WT human LCAT (d) or
human LCAT[T147I] found in a patient with fish eye disease (e). LCAT cDNA probes of WT and
LCAT mutants were provided by Dr. J.A. Kuivenhoven (Medical Center of Groningen)
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Previous studies showed that hemizygotes (compound heterozygotes for an
apoA-I null allele and an apoA-I(L141R)Pisa allele) had greatly decreased plasma
apoA-I levels and near absence of HDL cholesterol. Plasma from hemizygotes
contained preβ1-HDL and low concentration of small particles with alpha electro-
phoretic mobility (Miccoli et al. 1997). Heterozygotes for apoA-I(L141R)Pisa had
approximately half-normal values for HDL cholesterol and plasma apoA-I (Miccoli
et al. 1996; Pisciotta et al. 2003). Three male hemizygote patients and one hetero-
zygote patient developed coronary stenosis (Miccoli et al. 1996).
Other studies also showed that heterozygotes for apoA-I(L159R)FIN mutation
had greatly reduced plasma levels of HDL cholesterol and apoA-I (Miettinen
et al. 1997a) that was mainly distributed in the HDL3 region and had abnormal
electrophoretic mobility (Miettinen et al. 1997b; McManus et al. 2001). They also
had small-size (8–9 nm) HDL particles and decreased plasma and HDL cholesteryl
ester levels (Miettinen et al. 1997b; McManus et al. 2001). Human HDL containing
apoA-I(L159R)FIN had increased fractional catabolic rate compared to normal
HDL, indicating increased catabolism of the mutant apoA-I protein (Miettinen
et al. 1997a, b). Only one affected patient with this mutation had clinically
manifested atherosclerosis (Miettinen et al. 1997b).
To explain the etiology and potential therapy of genetically determined low
levels of HDL resulting from natural apoA-I mutations, we have studied the in vitro
and in vivo properties of the naturally occurring mutants, apoA-I[L141A]Pisa and
apoA-I[L159R]FIN (Koukos et al. 2007a). In vitro studies showed that both
mutants were secreted efficiently from cells, had normal ability to promote
ABCA1-mediated cholesterol efflux, but greatly diminished capacity to activate
LCAT (0.4–2 % of WT apoA-I). Adenovirus-mediated gene transfer showed that
compared to WT apoA-I, expression of either of the two mutants in apoA-I-
deficient (apoA-I/) mice greatly decreased total plasma cholesterol and apoA-I
levels as well as the CE/TC ratio compared to WT apoA-I (Table 2). Another
change that was associated with differences between the WT apoA-I and either of
Table 2 Plasma lipids and hepatic mRNA levels of apoA-I/ mice expressing WT and the













apo A-I WT 148 11 0.78 0.01 63 1 100 32 186 34
apoA-I (L141R)Pisa 23 0.4 0.44 0.03 11 2.8 88 9 17 4
apoA-I
(L141R)Pisa + LCAT
184 53 0.68 0.01 41 0.3 91 2 224 7
apoA-I (L159R)FIN 16 5 0.13 0.04 25 4 216 32 25 9
apoA-I
(L159R)FIN + LCAT
224 22 0.73 0.01 53 15 63 9 190 20
apo A-I (R159L)Oslo 43 13 0.23 0.01 36 4 117 30 66 31
apo A-I (R160L)Oslo 250 47 0.082 0.01 62 11 60 1 127 26
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the two mutants was the greatly decreased HDL cholesterol peak as determined by
FPLC fractionation of the plasma. Density gradient ultracentrifugation of plasma
showed great reduction of the amount of apoA-I that floated in the HDL region of
the apoA-I[L141R]Pisa mutant as compared to WT apoA-I (Fig. 5a, d). EM analysis
Fig. 5 (a–m) ApoA-I mutation that influence activity of LCAT. Analysis of plasma of apoA-I/
mice infected with adenoviruses expressing the WT apoA-I or the apoA-I[L141]Pisa mutant alone
or in combination with human LCAT by density gradient ultracentrifugation and SDS-PAGE (a, d,
g) as indicated. EM analysis of HDL fractions 6–7 obtained from apoA-I/ mice expressing the
WT apoA-I or the apoA-I[L141R]Pisa or mutant alone or in combination with human LCAT,
following density gradient ultracentrifugation of plasma, as indicated (b, e, h). Two-dimensional
gel electrophoresis of plasma of apoA-I/mice infected with adenoviruses expressing WT apoA-
I or the apoA-I[L141q]Pisa or mutant alone or in combination with human LCAT, as indicated (c, f,
i). Western blot analysis of plasma from apoA-I/ mice infected with adenoviruses expressing
either the control protein, GFP, or the WT apoA-I or the apoA-I(L141R)Pisa alone or in combina-
tion with human LCAT, as indicated at the top of the figure (j). Schematic representation showing
the pathway of biogenesis of HDL (k) and how the apoA-I(L141R)Pisa and apoA-I(L159R)FIN
mutants affect the esterification of cholesterol of the pre-HDL particles and prevent their conver-
sion to discoidal and spherical HDL, thus promoting their catabolism (l). Schematic representation
showing the inability of the apoA-I(R160L)Oslo mutant to convert the discoidal to spherical HDL
particles (m)
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of the HDL fractions obtained by density gradient ultracentrifugation showed the
presence of a large number of spherical HDL for WT apoA-I but only a few
spherical HDL particles for the apoA-I[L141R]Pisa mutant (Fig. 5b, e).
Two-dimensional gel electrophoresis of the plasma showed the formation of
small amount of preβ-HDL and large amount of α1, α2, α3, α4 HDL subpopulations
for the WT apoA-I and only preβ- and small-size α4 HDL subpopulations for the
apoA-I[L141R]Pisa mutant (Fig. 5c, f). Similar results were observed for apoA-I
[L159R]FIN (Koukos et al. 2007a).
Coinfection of apoA-I/ mice with adenoviruses expressing either of the two
mutants and human LCAT normalized the plasma apoA-I, the total plasma choles-
terol levels, and the CE/TC ratio (Table 2) and increased the HDL cholesterol peak
and the amount of apoA-I that floated in the HDL region (Fig. 5g). It also generated
large amount of spherical HDL (Fig. 5h) and restored the normal preβ- and α-HDL
subpopulations (Fig. 5i). Similar results were observed for apoA-I[L159R]FIN
(Koukos et al. 2007a).
Another interesting naturally occurring apoA-I mutation is the apoA-I
[R160L]Oslo. Previous studies showed that heterozygotes of apoA-I[R160L]Oslo
have approximately 60 and 70 % of normal HDL and apoA-I levels, respectively,
from preβ1-and small-size α-HDL particles and have a 30 % reduction in their
plasma LCAT activity (Leren et al. 1997). Gene transfer of the apoA-I[R160L]Oslo
mutant in apoA-I/ mice resulted in low plasma cholesterol and apoA-I levels
(Table 2) and generated discoidal particles with α4 electrophoretic mobility. The
aberrant phenotype could be corrected by co-expression of this mutant with
human LCAT (Koukos et al. 2007b).
Similar but not identical phenotypes were produced by expressing the
bioengineered apoA-I[R160V/H162A] and apoA-I[R149A] mutants and the natu-
rally occurring mutants apoA-I[R151C]Paris and apoA-I[L144R]Zaragosa (Haase
et al. 2011; Chroni et al. 2005a; Koukos et al. 2007b). This phenotype could be
corrected by co-expression of the mutant with human LCAT.
The last two mutations have not been associated with incidence of atherosclero-
sis in humans.
The apoA-I mutations discussed here offer a valuable tool to dissect the molec-
ular events which lead to the biogenesis of HDL and possibly to understand the
types of molecular interactions between apoA-I and LCAT which lead to the
activation of the enzyme.
In our case, residues R149, R153, and R160 were reported to create a positive
electrostatic potential around apoA-I. Mutations in these residues reduced drasti-
cally the ability of rHDL particles containing these apoA-I mutants to activate
LCAT in vitro (Roosbeek et al. 2001). Based on the “belt” model for discoidal
rHDL, these residues are located on the hydrophilic face of the apoA-I helices and
do not form intramolecular salt bridges in the antiparallel apoA-I dimer that covers
the fatty acyl chain of the discoidal particle. This arrangement allows in principle
these apoA-I residues to form salt bridges or hydrogen bonds with appropriate
residues of LCAT and thus contribute to LCAT activation.
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To explain the low HDL levels and the abnormal HDL phenotype of the apoA-
I/mice expressing the apoA-I(L141R)Pisa, we analyzed the relative abundance of
the endogenous mouse LCAT following gene transfer of the apoA-I(L141R)Pisa
mutant alone or in the presence of LCAT. This analysis showed a dramatic increase
of the mouse LCAT in mice expressing the apoA-I(L141R)Pisa mutant as compared
to mice expressing the WT apoA-I. Coinfection of apoA-I/mice with the apoA-I
(L141R)Pisa mutant and human LCAT restored the mouse LCAT to normal levels
(those observed in the presence of WT apoA-I) (Fig. 5j). The depletion of the
endogenous LCAT in mice expressing the mutant forms of apoA-I could be the
result of rapid degradation of endogenous mouse LCAT bound to minimally
lipidated apoA-I mutants possibly by the kidney.
The ability of the apoA-I[L141R]Pisa and apoA-I(L159R)FIN mutants to be
secreted efficiently from cells and to promote ABCA1-mediated cholesterol efflux
suggests that the functional interactions between apoA-I and ABCA1 that lead to
the lipidation of apoA-I are normal and the low apoA-I and HDL levels caused by
these two mutants are the result of fast removal of the lipidated nascent HDL
particles from the plasma compartment. This interpretation is supported by the
increased catabolic rate of HDL containing apoA-I(L159R)FIN (Miettinen
et al. 1997b) and the accumulation of proapoA-I in the plasma of hemizygotes for
apoA-I(L141R)Pisa (Miccoli et al. 1996). Accumulation of proapoA-I has been
previously observed in patients with Tangier disease (Zannis et al. 1982) that are
characterized by increased catabolic rate of HDL (Assmann et al. 2001). It has been
also shown previously that cubilin, a 600 KDa membrane protein, binds both apoA-
I and HDL and promotes their catabolism by the kidney (Kozyraki et al. 1999;
Hammad et al. 1999).
Previous studies showed that preβ-HDL is an efficient substrate of LCAT
(Nakamura et al. 2004b). In the presence of excess LCAT, the esterification of
the cholesterol of the newly formed preβ-particles appears to prevent their fast
catabolism and allows them to proceed in the formation of discoidal and spherical
HDL. In the case of the apoA-I[R160L]Oslo, the HDL pathway appears to be
inhibited in the step of the conversion of the discoidal to spherical HDL particles.
Figure 5k–m depicts the normal pathway of the biogenesis of HDL (Fig. 5k) and the
disruption of this pathway by the apoA-I(L141R)Pisa and apoA-I(L159R)FIN
(Fig. 5l) and apoA-I[R160L]Oslo mutants (Fig. 5m).
1.3 ApoA-I Mutations May Induce Hypertriglyceridemia
and/or Hypercholesterolemia
A series of apoA-I mutations had resulted in severe hypertriglyceridemia (Chroni
et al. 2004a; 2005b) (Table 3). The most recently studied case was apoA-I[D89A/
E91A/E92A] mutant where the charged residues were substituted by alanines. The
capacity of the apoA-I[D89A/E91A/E92A] mutant to promote ABCA1-mediated
cholesterol efflux and activate LCAT in vitro was approximately 2/3 of that of WT
apoA-I (Kateifides et al. 2011).
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In vivo studies using adenovirus-mediated gene transfer in apoA-I-deficient
mice showed that compared to WT apoA-I, the apoA-I[D89A/E91A/E92A] mutant
increased plasma and HDL cholesterol, reduced the CE/TC ratio, and caused severe
hypertriglyceridemia (Table 3) (Kateifides et al. 2011). Following density gradient
ultracentrifugation of plasma, approximately 40 % of the apoA-I mutant was
distributed in the VLDL/IDL region. In contrast, the WT apoA-I was distributed
in the HDL2/HDL3 region (Fig. 6a). Whereas the WT apoA-I formed spherical
HDL (Fig. 5b), the apoA-I[D89A/E91A/E92A] mutant formed mostly spherical
and few discoidal HDL particles as determined by EM (Fig. 6b). Two-dimensional
gel electrophoresis showed that WT apoA-I formed normal preβ- and α-HDL
subpopulations, whereas the apoA-I[D89A/E91A/E92A] mutants formed preβ-
and α4 HDL subpopulations (Fig. 6c) (Kateifides et al. 2011).
Co-expression of apoA-I[D89A/E91A/E92A] mutants and human lipoprotein
lipase in apoA-I-deficient mice abolished hypertriglyceridemia (Table 3),
redistributed apoA-I in the HDL2/HDL3 regions (Fig. 6d), restored in part the
α1,2,3,4 HDL subpopulations (Fig. 6f), but did not change significantly the choles-
terol ester to total cholesterol ratio (Table 3) or the formation of discoidal HDL
particles (Fig. 6e) (Kateifides et al. 2011).
The findings indicate that residues D89, E91, and E92 of apoA-I are important for
plasma cholesterol and triglyceride homeostasis as well as for the maturation of HDL.
The lipid, lipoprotein, and HDL profiles generated by another mutant, apoA-I
[K94A/K96A], where the charged residues were changed to Alanines, were similar
to those of WT apoA-I, indicating that the observed changes on the HDL phenotype
were unique for the charged residues D89, E91, and E92 (Kateifides et al. 2011).
Expression of a deletion mutant, apoA-I[Δ89-99], in apoA-I/ mice, increased
plasma cholesterol levels, increased the plasma preβ-HDL subpopulation,
generated discoidal HDL particles, but did not induce hypertriglyceridemia (Chroni
et al. 2005b).
Table 3 Plasma lipids and hepatic mRNA levels of apoA-I/ mice expressing WT and the













apo A-I/ 33 6 – 42 7 – –
WT apoA-I 268 55 0.72 0.06 70 11 100 32 283 84
apo A-I [D89A/
E91A/E92A]




122 56 0.44 0.14 49 16 41 6 99 18
apo A-I [Δ(62–
78)]
220 16 – 986 289 130 5 265 36
apo A-I [E110A/
E111A]
520 45 – 1,510 590 69 23 204 27
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Fig. 6 (a–h) Effects of apoA-I mutations on the induction of dyslipidemia. Location of the apoA-I
mutations that cause hypertriglyceridemia as indicated. Analysis of plasma of apoA-I/ mice
infected with adenoviruses expressing the apoA-I[D89A/E91A/E92A] mutant alone or in combi-
nation with human LPL, as indicated, by density gradient ultracentrifugation and SDS-PAGE (a,
d). EM analysis of HDL fractions 6–7 obtained from apoA-I/ mice expressing the apoA-I
[D89A/E91A/E92A] mutant alone or in combination with LPL, as indicated, following density
gradient ultracentrifugation of plasma (b, e). Two-dimensional gel electrophoresis of plasma of
apoA-I/ mice infected with adenoviruses expressing the apoA-I[D89A/E91A/E92A] mutant
alone or in combination with LPL, as indicated (c, f). Schematic representation of the solvent
inaccessible interhelical charged interactions of apoA-I dimers arranged in an antiparallel
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1.3.1 Potential Mechanism of Dyslipidemia Resulting from apoA-I
Mutations
The apoA-I[D89A/E91A/E92A] mutant has two similar characteristics with two other
mutants in different regions of apoA-I, the apoA-I[Δ(61-78)] and the apoA-I [E110A/
E111A] (Chroni et al. 2004a; 2005b), that cause hypertriglyceridemia (Table 3). The
first characteristic is that all three mutants caused accumulation of apoA-I in the VLDL/
IDL region. As shown previously, the accumulation of apoA-I in the lower densities
affects the in vitro lipolysis of the VLDL/IDL fraction by exogenous lipoprotein lipase
(Chroni et al. 2004a; 2005b). The second characteristic is that the three apoA-I mutants
have lost negative-charged residues that are present in the WT sequence. The E78,
D89, and E111 residues have the ability to form solvent inaccessible salt bridges with
positively charged residues present in the antiparallel apoA-I molecule of a discoidal
HDL particle (Segrest et al. 1999) (Fig. 6g).
In these arrangements of the apoA-I molecules on the HDL particle, residues
E78 in helix 2, D89 in helix 3, and E111 in helix 4 can form solvent inaccessible salt
bridges with residues R188 in helix 8, R177 in helix 7, and H155 in helix 6, respec-
tively, of the antiparallel strand. The affinity of all three mutants for triglyceride-
rich lipoprotein particles is further supported by binding studies to triglyceride-rich
emulsion particles (Gorshkova and Atkinson 2011).
It is interesting that in the 11/3 α-helical wheel residues E78, D89, and E111 are
all located in wheel position 2. With the exception of R188, all other five residues
involved in salt bridges are conserved in mammals.
The lipid and lipoprotein abnormalities observed in this mutant suggest that the
increased abundance of apoA-I in the VLDL/IDL region may create lipoprotein
lipase insufficiency that is responsible for the induction of hypertriglyceridemia.
The persistence of discoidal particle following the lipoprotein lipase treatment
indicates a direct effect of the [D89A/E91A/E92A] mutation in the activation of
LCAT in vivo. Previous studies showed that discoidal and small-size HDL particles
and LCAT associated with them may be catabolized fast by the kidney and thus
lead to LCAT insufficiency and reduced plasma HDL levels (Koukos et al. 2007a;
Timmins et al. 2005; Miettinen et al. 1997a).
It is conceivable that loosening of the structure of apoA-I around the D89 or E92
area due to the substitution of the original residues by alanines may provide new
surfaces for interaction of HDL with other proteins or lipoprotein particles such as
VLDL in ways that inhibit triglyceride hydrolysis. Furthermore, the accumulation
of discoidal HDL as well as the formation of preβ- and small α4 HDL particles as
shown by the in vivo experiments indicate that replacement of D89, E91, and E92
by A has a direct impact on the activation of LCAT.
The preceding analyses described in Figs. 3, 4, 5, and 6 demonstrate that expres-
sion of mutant apoA-I forms in different mouse models disrupted specific steps along
the pathway of the biogenesis of HDL and generated discrete lipid and HDL

Fig. 6 (continued) orientation in the belt model of rHDL (g). The pathway of HDL biogenesis.
Superimposed on the pathway are defects that inhibit different steps of this pathway (h)
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phenotypes (Zannis et al. 2006b). The phenotypes generated included inhibition of
the formation of HDL (Chroni et al. 2003, 2007; Fotakis et al. 2013a, b), generation of
unstable intermediates (Koukos et al. 2007a), inhibition of the activation of LCAT
(Chroni et al. 2005a; Koukos et al. 2007b), and increase in plasma cholesterol or
increase in both plasma cholesterol and triglycerides (Chroni et al. 2004a, 2005b;
Kateifides et al. 2011) (Fig. 6h).
1.4 ApoE and apoA-IV Participate in the Biogenesis of HDL
Particles Containing the Corresponding Proteins
Using adenovirus‐mediated gene transfer in apoA‐I‐ or ABCA1‐deficient mice, we
obtained unequivocal evidence that apoE of any phenotype participates in the
biogenesis of apoE‐containing HDL particles (HDL-E) using a similar pathway
that is used for the biogenesis of apoA-I-containing HDL particles (Kypreos and
Zannis 2007). In the initial experiments, gene transfer of an apoE4‐expressing
adenovirus increased both HDL and the triglyceride‐rich VLDL/IDL/LDL fraction
and generated discoidal HDL particles (Fig. 7a). Control experiments showed the
absence of discoidal or spherical HDL-size particles in the plasma of apoA-I-
deficient mice. The involvement of ABCA1 which was established by gene transfer
of apoE in ABCA1/ mice prior to and after treatment with apoE4, and indicated
that apoE4 could not promote formation of HDL particles in ABCA1/ mice
Fig. 7 EM analysis of apoA-I/ and ABCA1/ mice following infection with adenovirus
expressing human apoE4 as indicated (a, b). EM analysis of apoA-I/ mice following infection
with adenovirus expressing human apoE4 and LCAT (c). FPLC profile of apoA-I/ mice
expressing apoE4 and LCAT (d). Analyses of the plasma of apoA-I/ mice following infection
with adenovirus expressing human apoA-IV by density gradient ultracentrifugation and
SDS-PAGE (e), EM (f), and two-dimensional gel electrophoresis (g)
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(Fig. 7b). Other experiments in apoA-I/ x apoE/mice established that residues
1-202 of apoE are sufficient to promote biogenesis of apoE-containing HDL
(Vezeridis et al. 2011). Coinfection of apoA‐I/ mice with a mixture of
adenoviruses expressing both apoE4 and human LCAT converted the discoidal to
spherical HDL (Fig. 7c), suggesting that LCAT is essential for the maturation of the
discoidal apoE‐containing HDL to spherical particles (Kypreos and Zannis 2007).
The LCAT treatment also cleared the triglyceride‐rich lipoproteins and increased
the HDL cholesterol peak as determined by FPLC (Fig. 7d).
These findings suggest that in contrast to apoA-I where the C-terminal domain is
required for the biogenesis of HDL (Chroni et al. 2007), the carboxy-terminal
domain of apoE is not required for HDL formation. Overall, the findings indicate
that apoE has a dual functionality. In addition to its documented role in the
clearance of triglyceride‐rich lipoproteins, it participates in the biogenesis of
HDL-E in a process that is similar to that of apoA‐I.
HDL-E thus formed may have antioxidant and anti‐inflammatory functions
similar to those described for apoA‐I‐containing HDL, which may contribute to
the atheroprotective properties of apoE (Mineo et al. 2003; Plump et al. 1992;
Schaefer et al. 1986; Navab et al. 2000). ApoE‐containing HDL may also have
important biological functions in the brain (Li et al. 2003).
A similar set of gene transfer experiments in apoA-I/ and apoA-I/ x apoE/
mice also established that similar to apoE, apoA-IV also participates in the biogene-
sis of apoA-IV containing HDL (HDL-A-IV) and requires for this purpose the
activity of ABCA1 and LCAT (Duka et al. 2013).
Gene transfer of apoA-IV in apoA-I/ mice did not change plasma lipid levels.
Density gradient ultracentrifugation showed that apoA-IV floated in the HDL2/
HDL3 region (Fig. 7e), promoted the formation of spherical HDL particles as
determined by electron microscopy (Fig. 7f), and generated mostly α- and a few
preβ-HDL subpopulations as determined by two-dimensional gel electrophoresis
(Fig. 7g). When expressed in apoA-I/ apoE/ mice, apoA-IV increased
plasma cholesterol and triglyceride levels and shifted the distribution of the
apoA-IV protein in the lower density fractions. This treatment likewise generated
spherical particles and α- and preβ-like HDL subpopulations. Co-expression of
apoA-IV and LCAT in apoA-I/ mice restored the formation of HDL-A-IV.
Spherical and α-migrating HDL particles were not detectable following gene
transfer of apoA-IV in ABCA1/ or LCAT/ mice (Duka et al. 2013). The
ability of apoA-IV to promote biogenesis of HDL may explain previously reported
anti-inflammatory and atheroprotective properties of apoA-IV.
In vitro studies showed that lipid-free apoA-IV and reconstituted HDL-A-IV
promoted ABCA1- and scavenger receptor BI (SR-BI)-mediated cholesterol efflux,
with the same efficiency as apoA-I and apoE (Chroni et al. 2005c; Duka et al. 2013).
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1.5 Clinical Relevance of the Aberrant HDL Phenotypes
Genome-wide association studies indicated that specific gene loci were associated
with low or high HDL cholesterol and triglyceride levels and could in principle
affect the risk for coronary artery disease (CAD) (Teslovich et al. 2010). Prospec-
tive population studies have also shown that HDL has a protective role against CAD
(Gordon et al. 1989). The beneficial functions of HDL are also supported by the
atheroprotective effect of apoA-I overexpression in transgenic mice (Rubin
et al. 1991; Paszty et al. 1994) or rabbits (Emmanuel et al. 1996) or following
adenovirus-mediated gene transfer in mice (Belalcazar et al. 2003; Benoit
et al. 1999; Tangirala et al. 1999). The studies described above provide molecular
markers that could be used for the diagnosis, prognosis, and potential treatment of
HDL abnormalities or dyslipidemias associated with the biogenesis and remodeling
of HDL. Diagnostic phenotypes such as those depicted in Figs. 2a–c, 3a–d, 4a, b,
5d–f, and 6a–c can be used to assess defects in apoA-I, ABCA1, and LCAT
respectively.
The HDL phenotypes observed in human patients carrying the apoA-I
[L141R]Pisa and apoA-I[L159R]Fin mutations resemble closely the phenotypes
observed in apoA-I-deficient mice expressing these mutants and indicate the valid-
ity of the gene transfer studies in mice to establish defects in HDL biogenesis. It is
possible that phenotypes generated by mutagenesis of apoA-I may exist in the
human population and can be detected by one or more of the analyses described
previously. The correction of the aberrant HDL phenotypes by treatment with
LCAT suggests a potential therapeutic intervention for HDL abnormalities that
result from specific mutations in apoA-I or conditions that result in low HDL levels.
Additional supporting evidence has been obtained by adenovirus-mediated gene
transfer of human LCAT in squirrel monkeys. This treatment increased two-fold the
HDL levels without affecting apoA-I levels, increased the size of HDL, and
decreased apoB levels (Amar et al. 2009).
The potential contribution of apoA-I mutations to hypertriglyceridemia in
humans is interesting. Hypertriglyceridemia resulting from apoA-I mutations may
be further aggravated by other genetic and environment factors such as diabetes and
thyroid status. The contribution of apoA-I mutations to hypertriglyceridemia could
be addressed in future studies in selected populations of patients with hypertrigly-
ceridemia of unknown etiology.
2 Remodeling and Catabolism of HDL
Following synthesis by the liver and the intestine, HDL is remodeled by various
plasma proteins and is subsequently catabolized in the plasma by cell receptors and
other plasma proteins (Fig. 8a–d).
Turnover studies showed that the mean plasma residence time of radiolabeled
125I-HDL2 and HDL3 was 6 days for normal subjects (Schaefer et al. 1979) and
0.22 days for patients with Tangier disease (Schaefer et al. 1981). Using stable
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isotope turnover kinetic measurements, the resident time was estimated to be 4–5
days. The fractional catabolic rates (FCR) were expressed as pools per day, and the
secretion rates that were determined by this method for men and women were
similar. The FCR were not affected significantly by diet, diabetes, or LDL receptor
defects, but it was increased in subjects with increased glucose tolerance (Marsh
et al. 2000). HDL remodeling affects the structure and metabolic turnover of HDL
and generates a dynamic mixture of discrete HDL subfractions that vary in size,
shape, apolipoprotein, and lipid composition and functions (Siggins et al. 2007;
Fielding and Fielding 2007; Xu and Nilsson-Ehle 2007; Harder and McPherson
2007).
Remodeling of HDL by the action of hepatic lipase (HL) and endothelial lipase
(EL) involves hydrolysis of residual triglycerides and some phospholipids of HDL
(Maugeais et al. 2003a; Santamarina-Fojo et al. 2004), leads to the conversion of
HDL2 to HDL3 and preβ-HDL (Ishida et al. 2003; Krauss et al. 1974; Breckenridge
et al. 1982; Brunzell and Deeb 2001), and accelerates the catabolism of HDL.
Preβ-HDL formation also requires the functions of apolipoprotein M (apoM)
(Wolfrum et al. 2005).
Portion of the cholesteryl esters formed by the actions of LCAT can be trans-
ferred to VLDL/IDL/LDL by the cholesteryl ester transfer protein (CETP)
Fig. 8 (a–d) Schematic representation of the pathway of HDL remodeling by the action of hepatic
and endothelial lipase (a), CETP (b), PLTP (c), and SR-BI, ABCG1, and HDL holoparticle uptake
by F1-ATPase (d)
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(Hopkins and Barter 1980; Barter et al. 2003) The phospholipid transfer protein
(PLTP) can transfer the phospholipids from VLDL/IDL to the HDL particle during
lipolysis to generate HDL2 and can also convert HDL3 particles to HDL2 and
preβ-HDL (Tall et al. 1983; Lusa et al. 1996). HDL-binding proteins/receptors or
transporters have been documented at all steps of HDL metabolism and involve the
SR-BI, which is mostly expressed in hepatocytes, macrophages, and steroidogenic
tissues and mediates selective CE uptake by the cells and tissues and cholesterol
efflux (Gu et al. 1998; Krieger 1999; Rohrl and Stangl 2013; Pagler et al. 2006a);
the ABCG1, which mediates cholesterol efflux (Nakamura et al. 2004a); the ecto-
F1-ATPase subunit, which mediates HDL holoparticle uptake by the liver (Martinez
et al. 2003, 2007); and the cubilin/megalin receptors for removal of apoA-I and
preβ-HDL by the kidney (Martinez et al. 2007).
2.1 ATP-Binding Cassette Transporter G1
HDL can be remodeled following interactions with ABCG1, a 67 kDa protein,
which is a member of the ABC family of half transporters. ABCG1 is expressed in
the spleen, thymus, lung, and brain (Savary et al. 1996; Croop et al. 1997;
Nakamura et al. 2004a) and was reported to be localized on plasma membrane,
the Golgi, and recycling endosomes (Wang et al. 2006; Vaughan and Oram 2005;
Sturek et al. 2010a; Xie et al. 2006a). The expression of ABCG1 is induced by LXR
agonists in macrophages and the liver or by cholesterol loading in macrophages
(Klucken et al. 2000; Venkateswaran et al. 2000; Wang et al. 2006).
Overexpression of ABCG1 promotes cholesterol efflux from different cells to
HDL but not to lipid-free apoA-I (Wang et al. 2004, 2006; Nakamura
et al. 2004a; Vaughan and Oram 2005) (Fig. 8d). HDL obtained from CETP-
deficient subjects or patients treated with the CETP inhibitors torcetrapib or
anacetrapib was shown to have enhanced ability to promote ABCG1-dependent
cholesterol efflux from macrophages (Matsuura et al. 2006; Yvan-Charvet
et al. 2007, 2010). ABCG1-mediated cholesterol efflux to HDL is abolished by
mutations in the ATP-binding Walker A motif indicating that the ATP-binding
domain in ABCG1 is essential for both lipid transport activity and protein traffick-
ing (Vaughan and Oram 2005). In addition, ABCG1 was shown to promote efflux
of 7-ketocholesterol and related oxysterols from macrophages and endothelial cells
to HDL, thus protecting cells from apoptosis (Terasaka et al. 2007; Li et al. 2010).
In macrophages, ABCG1, and not SR-BI or ABCA1, has been shown recently to be
primarily responsible for free cholesterol mobilization to rHDL (Cuchel
et al. 2010a).
Studies in ABCG1-deficient mice also suggested that ABCG1 plays a critical
role in the efflux of cellular cholesterol to HDL (Kennedy et al. 2005). Studies using
intraperitoneal injection of mice with [3H]cholesterol-labeled J774 macrophages
with either increased or reduced ABCG1 expression, as well as primary
macrophages lacking ABCG1 expression, and measurement of the macrophage-
derived [3H]cholesterol levels in plasma and feces, showed that ABCG1 plays a
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critical role in promoting macrophage reverse cholesterol transport in vivo (Wang
et al. 2007). Nevertheless, the studies in ABCG1-deficient and ABCG1 transgenic
mice showed that plasma lipids, HDL, and other lipoprotein levels were not
affected (Kennedy et al. 2005; Out et al. 2007; Burgess et al. 2008). Other studies
showed that loss of ABCG1 gene in mice results in massive lipid accumulation in
hepatocytes and in macrophages within multiple tissues, with the more marked
accumulation in pulmonary macrophages (Kennedy et al. 2005; Out et al. 2006,
2007; Burgess et al. 2008; Baldan et al. 2006; Ranalletta et al. 2006; Wojcik
et al. 2008). In addition, ABCG1 has been suggested to mediate cholesterol efflux
to HDL particles from other cell types than macrophages, including adipocytes
(Zhang et al. 2010) and human placental endothelial cells, where it may facilitate
the transfer of maternal cholesterol to the fetus (Stefulj et al. 2009).
Previous studies indicated that there is little or no specificity of ABCG1 for the
acceptor of cholesterol since LDL, HDL2, HDL3, phospholipid/apoA-I particles of
various sizes and small unilamellar particles can function as acceptors for choles-
terol from cells in an ABCG1-mediated manner (Sankaranarayanan et al. 2009;
Favari et al. 2009). However, a recent study by us showed that the ABCG1-
mediated efflux of cholesterol to rHDL containing different apoA-I mutants is
diminished by deletion of the carboxyl-terminal domain 185-243 from full-length
apoA-I (Daniil et al. 2013). Analysis of rHDL used in these studies suggested that
the impairment of ABCG1-mediated cholesterol efflux is not due to major
differences in particle composition or size between rHDL particles containing
WT apoA-I or apoA-I[Δ(185-243)].
The mechanism by which ABCG1 promotes sterol efflux to extracellular
acceptors has not been resolved. The earlier studies failed to detect specific HDL
association in BHK or HEK293 cells overexpressing the human ABCG1 (Wang
et al. 2004; Sankaranarayanan et al. 2009). Also the initial studies had suggested
that ABCG1 is localized to both the plasma membrane and internal membrane
structures (Vaughan and Oram 2005; Wang et al. 2006; Xie et al. 2006b), while
more recent studies suggested that ABCG1 is localized to endosomes and recycling
endosomes (Sturek et al. 2010b; Tarling and Edwards 2011). It has been proposed
that ABCG1 could transport sterols across the bilayer of endosomes before their
fusion with the plasma membrane and thus redistribute these sterols to the outer
leaflet of the plasma membrane and facilitate their subsequent efflux of sterols to
HDL or other acceptors (Tarling and Edwards 2011; Vaughan and Oram 2005).
However, the similar pattern of lipid-free and rHDL-bound apoA-I mutants to
promote ABCA1- and ABCG1-mediated cholesterol efflux is compatible with a
transient localization of ABCG1 in the plasma membrane that will allow its
interaction with lipoprotein acceptors (Chroni et al. 2003, 2004b; Daniil et al.
2013). The similar cholesterol efflux capacity of lipid-free and lipidated apoA-I
mutants could favor a model where lipid-free apoA-I is lipidated in an ABCA1-
mediated process, changes its conformation, and subsequently accepts more choles-
terol from membrane pools generated by ABCA1 or ABCG1.
The different capacity of rHDL-associated apoA-I[Δ(185-243)] mutant to pro-
mote ABCG1-mediated cholesterol and 7-ketocholesterol efflux (Daniil et al. 2013)
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may be related to the looser association of 7-ketocholesterol with the plasma
membrane compared to cholesterol (Kan et al. 1992).
The finding that lipid-free and lipid-bound apoA-I[Δ(185-243)] has reduced
capacity to promote ABCA1- and ABCG1-mediated cholesterol efflux, respec-
tively, may have physiological significance since proteolysis of HDL-associated
apoA-I in vivo may affect its ability to promote cholesterol efflux from
macrophages. In this regard, proteolysis of apoA-I by metalloproteinases present
in the arterial wall or alveolar macrophages (Russell et al. 2002; Galis et al. 1995)
produces various fragments that correspond to apoA-I cleaved after residues 191 or
188 and are compatible in size with apoA-I[Δ(185-243)] (Lindstedt et al. 1999;
Eberini et al. 2002). This may explain the accumulation of foam cells containing
high cholesterol levels in alveolar macrophages of ABCG1-deficient mice
(Kennedy et al. 2005; Out et al. 2006).
A recent study using high-density genotyping arrays containing single-
nucleotide polymorphisms suggested an association between HDL cholesterol
levels in humans and ABCG1 (Edmondson et al. 2011). Recent genetic association
studies in humans identified functional variants in ABCG1 associated with
increased risk of coronary artery disease (Xu et al. 2011; Schou et al. 2012),
suggesting an important role of ABCG1 in the protection from atherosclerosis
and cardiovascular disease.
2.2 Phospholipid Transfer Protein
Phospholipid transfer protein (PLTP) transfers phospholipids, diacylglycerol (Rao
et al. 1997), free cholesterol (Nishida and Nishida 1997), R-tocopherol (vitamin E)
(Kostner et al. 1995), and lipopolysaccharide among lipoproteins and between
lipoproteins and cells (Hailman et al. 1996; Levels et al. 2005) (Fig. 8c). In vitro
studies have identified a number of functions for PLTP in HDL metabolism (Albers
and Cheung 2004; Siggins et al. 2007). PLTP displays two major functions in
circulation: (1) it transforms HDL particles in a conversion or fusion process
whereby small HDL3 particles are fused leading to the generation of large fused
HDL particles and preβ-HDL that can participate in cholesterol removal from cells
(Vikstedt et al. 2007a), and (2) it transfers post-lipolytic VLDL surface
phospholipids to HDL (Albers and Cheung 2004; Siggins et al. 2007). Functions
of PLTP which may influence the formation of atherosclerotic lesions include the
generation of acceptors for lipid efflux from cells, regulation of plasma HDL levels,
protection of lipoproteins from oxidation, and regulation of production of athero-
genic lipoproteins (Jiang et al. 2001).
In human plasma, two distinct forms of PLTP are present, one with high activity
(HA-PLTP) and the other with low activity (LA-PLTP) (Oka et al. 2000;
Karkkainen et al. 2002). It was reported that phospholipid transfer activity is a
prerequisite for efficient PLTP-mediated HDL enlargement (Huuskonen
et al. 2000) and that enrichment of triglyceride in the HDL core could promote
such fusion (Rye et al. 1998). Of these two forms, only the high specific activity
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PLTP promotes macrophage cholesterol efflux via fusion of HDL particles that
leads to the release of lipid-poor preβ-mobile apoA-I particles which act as efficient
cholesterol acceptors (Vikstedt et al. 2007a). The mechanisms by which LA-PLTP
is generated and its physiological functions are currently unknown. However, since
apoE is able to interact with PLTP, and apoE-containing proteoliposomes can
activate inactive or low active PLTP, the presence of apoE in PLTP complexes is
expected to enhance PLTP activity. This is consistent with the suggestion that apoE
may play a role in regulating the PLTP activity level in plasma (Janis et al. 2005).
HA- and LA-PLTP forms are surface-active proteins, and the low active form was
demonstrated to dock more strongly onto a phospholipid monolayer surface as
compared to HA-PLTP form (Setala et al. 2007). It is therefore possible that
LA-PLTP form could play other important lipid transfer-independent functions
such as signaling on cell surface as suggested (Albers et al. 2012).
Although the role of PLTP in lipoprotein metabolism and atherogenesis has been
intensively studied in gene-targeted mouse models and using in vitro experiments,
the physiological role of PLTP in human metabolism is far from being resolved.
Genetic approach has provided some evidence that genetic variation at the PLTP
locus affects its phospholipid transfer activity and HDL particle size and might
highlight its relevance in cholesterol efflux process (Vergeer et al. 2010a). PLTP-
deficient mice have a marked decrease in HDL and apoA-I (Jiang et al. 1999) but
reduced atherosclerosis in the background of apoE/ or apoB-transgenic mice
(Jiang et al. 2001). It has also been reported that macrophage-derived PLTP
contributes significantly to total plasma PLTP activity and deficiency of PLTP in
macrophages leads to reduced atherosclerosis in LDLr/ mice (Vikstedt
et al. 2007b). There is also an interesting interaction between PLTP and CETP
since it was demonstrated that purified PLTP enhances cholesteryl ester transfer
from HDL3 to VLDL (Tollefson et al. 1988), although PLTP has no cholesterol
ester transfer activity of its own. Moreover, CETP transgenic/PLTP KO mice have
significantly lower plasma CETP activity as compared to that of CETP transgenic
mice (Kawano et al. 2000). Currently, the physiological relevance of this PLTP-
CETP interaction in HDL metabolism is poorly understood.
2.3 apoM
Apolipoprotein M (apoM), which is also involved in HDL remodeling (Fig. 8a), is a
26 kDa glycoprotein that belongs to the lipocalin protein superfamily and has been
shown to bind lipophilic ligands in its hydrophobic binding pocket (Xu and
Dahlback 1999; Nielsen et al. 2009; Dahlback and Nielsen 2009; Hu et al. 2010).
It is secreted by the liver and to a lesser extent by the kidney and associates with
HDL through its retained N-terminal signal peptide (Christoffersen et al. 2008a;
Axler et al. 2008) and to a lesser extent with other lipoproteins. ApoM is involved in
the recycling of small lipophilic ligands via the multi-ligand receptor megalin
(Nielsen et al. 2009) and has been shown to participate in the remodeling and
maturation of HDL in plasma.
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Studies in humans and in mice overexpressing or lacking apoM have shown a
positive association between plasma apoM levels and total as well as HDL and LDL
cholesterol concentrations (Axler et al. 2007; Plomgaard et al. 2009; Christoffersen
et al. 2008b). Lack of hepatocyte nuclear factor-1α (HNF-1α) (Shih et al. 2001) or
inhibition of apoM expression in C57BL/6 mice injected with small interfering
RNA for apoM (Wolfrum et al. 2005) is characterized by diminished concentration
of preβ-HDL particles and presence of large-size HDL particles. In vitro
experiments using plasma obtained from WT mice, apoM knockout, and apoM
transgenic mice showed that apoM increases the formation of preβ-HDL particles
following incubation of the plasma at 37 C (Christoffersen et al. 2008b).
These studies also indicate that apoM-containing HDL particles isolated from
human plasma and the plasma of apoM transgenic mice have increased capacity to
stimulate cholesterol efflux from macrophage foam cells and are more efficient in
protecting against LDL oxidation (Wolfrum et al. 2005; Christoffersen
et al. 2008b). Cell culture studies indicated that expression of apoM in cells
transfected with ABCA1 increases the size of preβ-HDL (Mulya et al. 2010).
Reduced plasma apoM levels have been reported in animal models of diabetes
and some patients with diabetes and metabolic syndrome (Plomgaard et al. 2009;
Dullaart et al. 2009; Xu et al. 2006), indicating potential involvement of apoM in
the development of diabetes. Genetic linkage studies in Chinese populations have
also associated two single-nucleotide polymorphisms (SNPs) located in the apoM
proximal promoter region (SNP T-778C and SNP T-855C) with the development of
coronary artery disease (Xu et al. 2008; Jiao et al. 2007) and one of them (the
T-778C) associated with susceptibility to coronary artery disease.
Adenovirus-mediated gene transfer of apoM in LDL-receptor-deficient mice or
hepatic overexpression of apoM in apoM transgenic mice partially protected the
mice from atherosclerosis development (Christoffersen et al. 2008b; Wolfrum
et al. 2005). Data accumulating until now strongly suggest a protective role for
apoM, and the protection might be mediated via HDL.
2.4 Hepatic Lipase and Endothelial Lipase
HDL is first remodeled in the circulation and subsequently catabolized by cells and
tissues. Hepatic lipase (HL) and endothelial lipase (EL) are two plasma lipases
playing an important role in HDL remodeling (Fig. 8a). HL and EL have specificity
primarily for phospholipids and to a lesser extend for triglycerides of apoB-
containing lipoprotein remnants and large HDL (Maugeais et al. 2003a;
Santamarina-Fojo et al. 2004). HL-deficient mice exhibit elevated levels of large
HDL particles enriched in phospholipids and apoE (Homanics et al. 1995) and
reduced atherosclerosis in the background of apoE/mice (Karackattu et al. 2006;
Mezdour et al. 1997). In contrast, overexpression of HL in mice reduced plasma
HDL levels (Braschi et al. 1998). A rat liver perfusion of human native HDL2 or
triglyceride-enriched HDL promoted the formation of the preβ1-HDL subspecies
and a reduction of the α-HDL2 (Barrans et al. 1994). These changes were attributed
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to the triglyceride lipase activity of HL (Barrans et al. 1994). Characterization of
preβ1-HDL showed that these particles contain one to two molecules of apoA-I,
associated with phospholipids, and some free and esterified cholesterol (Guendouzi
et al. 1999). When compared to triglyceride-rich HDL2, remnant-HDL2 had lost on
the average one molecule of apoA-I, 60 % of triglycerides, and 15 % of
phospholipids. The estimated composition supported the hypothesis that HL had
splitted the initial particle into one preβ1-HDL and one remnant-HDL2. Remnant-
HDL2 had different composition and properties from HDL3, suggesting that HL
did not promote the direct conversion of HDL2 to HDL3 (Guendouzi et al. 1999).
Analysis of HL transgenic rabbits suggested that HL reduces the size of α-migrating
HDL and increases the rate of catabolism of apoA-I (Kee et al. 2002). Cell studies
showed that HL promotes selective HDL3 cholesterol ester uptake independent
from SR-BI and that proteoglycans are needed for the HL action on selective CE
uptake (Brundert et al. 2003). Earlier studies in mice deficient in both HL and EL
suggested an additive effect of HL and EL on plasma HDL levels but not on
macrophage-mediated reverse cholesterol transport in mice (Brown et al. 2010).
However, a recent study demonstrated that targeted inactivation of both HL and EL
in mice promoted macrophage-to-feces RCT and enhanced HDL antioxidant
properties (Escola-Gil et al. 2013).
HL-deficient patients have elevated plasma concentrations of cholesterol in the
HDL and β-VLDL and increased concentration of triglycerides and phospholipids
in the LDL and HDL (Breckenridge et al. 1982). Analyses carried out in complete
and partial HL-deficient subjects as well as in normotriglyceridemic and hyper-
triglyceridemic controls suggested that HL activity is important for physiologically
balanced HDL metabolism (Ruel et al. 2004). However, the presence of HL may
not be necessary for normal HDL-mediated reverse cholesterol transport process
and is not associated with pro-atherogenic changes in HDL composition and
metabolism (Ruel et al. 2004). In addition, another Mendelian randomization
study showed that subjects with loss-of-function genetic variants of HL have
elevated levels of HDL cholesterol, but are not associated with risk of ischemic
cardiovascular disease and therefore may not be protected against ischemic cardio-
vascular disease (Johannsen et al. 2009).
Endothelial lipase (EL) has phospholipase activity (mostly PLA1 activity) and
low levels of triglyceride lipase activity (Jaye et al. 1999). Overexpression of EL in
mice markedly decreased plasma HDL cholesterol and apoA-I levels, had a modest
effect on apoB-containing lipoproteins, and increased 2.5–3-fold the uptake of the
HDL by the kidney and the liver (Ishida et al. 2003; Maugeais et al. 2003a). In
contrast, the EL deficiency in mice increased HDL cholesterol levels (Ishida
et al. 2003; Ma et al. 2003) and reduced atherosclerosis in the background of
apoE/ mice (Ishida et al. 2004). Analysis of atherosclerosis prone LDLR/ x
ApoB(100/100) mice suggested that EL and the HDL cholesterol levels were
regulated by SREBPs and VEGF-A (Kivela et al. 2012). Overexpression of EL in
mice markedly decreased plasma HDL cholesterol and apoA-I levels and had a
modest effect on apoB-containing lipoproteins (Maugeais et al. 2003b; Ishida
et al. 2003). Furthermore, the HDL phospholipid and cholesteryl ester content
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decreased, while HDL triglyceride content increased (Nijstad et al. 2009) and the
free cholesterol content remained unaltered. Fast protein liquid chromatography
analysis and agarose gel electrophoresis showed that the expression of EL resulted
in the generation of small preβ-HDL particles (Nijstad et al. 2009). In addition,
overexpression of EL increased the selective uptake of hepatic HDL cholesteryl
ester by SR-BI as well as hepatic holoparticle uptake. This resulted in a dramatic
increase in the uptake of the HDL protein, but not the cholesteryl ester moieties,
into the kidneys (Nijstad et al. 2009). These data support a model in which
EL-mediated phospholipid hydrolysis of HDL destabilizes the particle, resulting
in the shedding of poorly lipidated apoA-I from the particle surface, which are
preferentially cleared by the kidneys and via increased selective uptake by SR-BI.
Several genetic EL variants have been reported to be associated with plasma
HDL-C levels (deLemos et al. 2002; Edmondson et al. 2009), and genome-wide
association studies have shown that single-nucleotide polymorphisms (SNPs) near
LIPG (EL) are associated with plasma HDL-C levels (Kathiresan et al. 2008a,
2009; Teslovich et al. 2010). However, the relationship of genetic variation in the
EL locus with the risk for coronary artery disease remains uncertain (Vergeer
et al. 2010b). A newer study showed that carriers of an EL mutant characterized
by complete loss of function had significantly higher plasma HDL cholesterol
levels compared to carriers having partial loss-of-function mutations (Singaraja
et al. 2013). Apolipoprotein B-depleted serum from carriers of HL with complete
loss of function had significantly enhanced capacity to promote cholesterol efflux as
compared to apoB-depleted serum obtained from HL carriers with partial loss of
function (Singaraja et al. 2013). In the same study, it was reported that carriers of
certain EL mutations exhibited trends toward reduced coronary artery disease in
four independent cohorts (Singaraja et al. 2013).
2.5 Cholesteryl Ester Transfer Protein
Cholesteryl ester transfer protein (CETP) promotes the transfer of cholesteryl esters
from HDL to VLDL, IDL, and LDL in exchange for triglycerides (Fig. 8b). It was
estimated that 66 % of the cholesteryl esters of HDL return to the liver by the action
of CETP, indicating an important role of CETP in reverse cholesterol transport
(Barter et al. 2003), and 33 % by the action of SR-BI (Fielding and Fielding 2007).
Deficiency in CETP in humans is associated with increased plasma levels of HDL
(hyperalphalipoproteinemia) (Inazu et al. 1990; Maruyama et al. 2003) and
decreased levels of small preβ1-HDL particles (Arai et al. 2000; Asztalos 2004).
An early study showed that the hyperalphalipoproteinemia and high plasma HDL
cholesterol levels in a Japanese family without incidence of atherosclerosis was the
result of deficiency in CETP (Koizumi et al. 1985). Inhibition of CETP activity by
CETP inhibitors increased HDL cholesterol levels and the size of HDL particle and
decreased LDL cholesterol levels in human subjects, but did not increase
atheroprotection (Landmesser et al. 2012; Brousseau et al. 2004; de Grooth
et al. 2002). However, subsequent studies indicated that heterozygous mutations
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in CETP increase the risk for CAD (Hirano et al. 1995, 1997; Zhong et al. 1996).
The effect of CETP on the HDL pathway was also studied in mice expressing the
human CETP gene. CETP transgenic mice have a significant decrease in apoA-I
and HDL levels (Melchior et al. 1994) and increased preβ-HDL levels (Francone
et al. 1996) and are susceptible to atherosclerosis in the background of apoE/ or
LDLr/ mice (Plump et al. 1999).
2.6 Scavenger Receptor BI
2.6.1 Role of SR-BI in HDL Remodeling Based on Its In Vitro
Interactions with Its Ligands
SR-BI is an 82 kDa membrane glycoprotein consisting of a large extracellular
domain, two transmembrane domains, and two cytoplasmic amino and carboxy-
terminal domains (Krieger 1999). SR-BI is primarily expressed in the liver, steroido-
genic tissues, and endothelial cells but is also found in other tissues (Acton
et al. 1996), and it binds a variety of ligands including HDL, LDL, VLDL, and
modified lipoproteins. SR-BI has also been shown to affect chylomicron metabolism
in vivo and bind non-HDL lipoproteins in vitro (Out et al. 2004b, 2005; Krieger
1999, 2001; Acton et al. 1994, 1996; Murao et al. 1997). The most important
property of SR-BI is considered its ability to act as the HDL receptor (Fig. 8d).
It has been shown that SR-BI binds to native HDL and discoidal reconstituted
HDL containing apoA-I or apoE, through their apolipoprotein moieties (Krieger
2001; Chroni et al. 2005c; Liadaki et al. 2000; Xu et al. 1997). When it is bound to
HDL, SR-BI mediates selective uptake of cholesteryl ester, triglycerides,
phospholipids, and vitamin E from HDL to cells (Acton et al. 1996; Greene
et al. 2001; Thuahnai et al. 2001; Stangl et al. 1999; Gu et al. 1998, 2000b;
Urban et al. 2000). It also promotes bidirectional movement of unesterified choles-
terol (Ji et al. 1997; Gu et al. 2000a). Interactions of HDL with SR-BI are
responsible for mobilization of free cholesterol from the whole body
(Ji et al. 1997; Gu et al. 2000a; Cuchel et al. 2010b). SR-BI-mediated HDL
holoparticle endocytosis may also be involved in SR-BI-mediated selective CE
uptake under certain conditions in some types of cells (Pagler et al. 2006b; Ahras
et al. 2008). To understand the molecular interaction of SR-BI with HDL, SR-BI
mutants which display altered biological functions were generated by in vitro
mutagenesis. A SR-BI[M158R] mutant does not bind HDL (Gu et al. 2000a). A
SR-BI[Q402R/Q418R] mutant also does not bind HDL, but in contrast with the first
mutant, it binds LDL (Gu et al. 2000a; b). A SR-BI[G420H] mutant has normal
selective cholesteryl ester uptake but reduced cholesterol efflux to HDL and
reduced hydrolysis of internalized cholesteryl esters (Parathath et al. 2004). Cell
culture cholesterol efflux studies using rHDL containing mutated apoA-I and these
SR-BI mutants showed that the greater reduction of cholesterol efflux in cells
expressing WT SR-BI was with the mutants apoA-I[D102A/D103A] and apoA-I
[R160V/H162A] (21 % and 49 %, respectively) (Liu et al. 2002).
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Follow-up in vivo studies showed apoA-I-deficient mice infected with an ade-
novirus expressing the apoA-I[D102A/D103A] had an HDL phenotype that resem-
bled that of WT apoA-I (Chroni et al. 2005a). In contrast, mice expressing the
apoA-I[R160V/H162A] had a phenotype similar to that described for apoA-I
[R160L]Oslo that could be corrected by co-expression of the apoA-I[R160L]Oslo
mutant and human LCAT (Chroni et al. 2005a). Following density gradient ultra-
centrifugation, the apoA-I[R160V/H162A] mutant that floated in the HDL region
was decreased relatively to WT apoA-I, and it was shifted toward the HDL3 region
(Chroni et al. 2005a).
When the mutant SR-BI[M158R] was examined, several apoA-I mutants tested
had reduced efflux and bound less tightly compared to WT apoA-I with the
exception of rHDL that contained the mutant apoA-I[A160V/H162A]. The binding
of this mutant was almost as tight to the cells that expressed SR-BI[M158R] mutant
as it was for the cells that expressed WT SR-BI (Liu et al. 2002). Based on these
findings, it was suggested that efficient SR-BI-mediated cholesterol efflux requires
not only direct binding (Gu et al. 2000a) but also the formation of a productive
complex between SR-BI and the rHDL particle (Liu et al. 2002).
2.6.2 In Vivo Functions of SR-BI
Expression of SR-BI in the liver was shown to be critical for the control of plasma
levels of HDL cholesterol (HDL-C) (Leiva et al. 2011; Zhang et al. 2007), and its
expression in the steroidogenic tissues is important for synthesis of steroid
hormones (Landschulz et al. 1996; Krieger 1999). Transgenic mice expressing
SR-BI in the liver had decreased apoA-I and HDL cholesterol levels and increased
clearance of VLDL and LDL (Wang et al. 1998; Ueda et al. 1999). SR-BI-deficient
mice had decreased HDL cholesterol clearance (Out et al. 2004a), twofold
increased plasma cholesterol, and presence of large-size abnormal apoE-enriched
particles that were distributed in the HDL/IDL/LDL region (Rigotti et al. 1997).
The in vivo phenotypes generated by overexpression or deficiency of SR-BI are
consistent with its in vitro functions to promote selectively lipid transport from
HDL to cells and efflux of free cholesterol from cells. SR-BI has also been shown to
affect chylomicron metabolism in vivo (Out et al. 2004b; 2005).
Deficiency of SR-BI in mice reduced greatly the cholesteryl ester stores of
steroidogenic tissues and decreased the secretion of biliary cholesterol by approxi-
mately 50 %. However, the SR-BI deficiency did not affect the secretion of the pool
size of bile acids or the fecal secretion of bile acids and the intestinal cholesterol
absorption (Rigotti et al. 1997; Mardones et al. 2001). These findings established
that two important functions of SR-BI are the transfer of the CE of HDL to the liver
and subsequent incorporation into the bile for excretion (Rigotti et al. 1997;
Mardones et al. 2001) and the delivery of cholesteryl esters to the steroidogenic
tissues where it is utilized for synthesis of steroid hormones (Ji et al. 1999). Further-
more SR-BI controls the concentrations and composition of plasma HDL (Krieger
2001; Wang et al. 1998; Ueda et al. 1999; Rigotti et al. 1997; Webb et al. 2002) and
protects different mouse models from atherosclerosis (Hildebrand et al. 2010;
Arai et al. 1999; Ueda et al. 2000; Kozarsky et al. 2000; Huszar et al. 2000;
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Trigatti et al. 1999; Braun et al. 2002, 2003; Karackattu et al. 2005; Zhang
et al. 2005).
SR-BI deficiency also caused defective maturation of oocytes and red blood cells
due to accumulation of cholesterol in the plasma membrane of progenitor cells
(Trigatti et al. 1999; Holm et al. 2002) and caused infertility in the female but not
the male mice (Trigatti et al. 1999; Yesilaltay et al. 2006a). The infertility could be
corrected by restoration of SR-BI gene by adenovirus-mediated gene transfer
(Yesilaltay et al. 2006b). Subsequent experiments showed a negative correlation
of follicular HDL cholesterol levels in women and embryo fragmentation during
in vitro fertilization (Browne et al. 2009). Taken together these data suggest a role
of HDL in oocyte development and embryogenesis. The SR-BI-mediated selective
uptake of the CE of HDL by the liver is a complex process and requires the
functions of a liver-specific protein, PDZK1, that contains four PDZ domains that
can recognize the C-terminal region of SR-BI. Interaction of PDZK1 with the
C-terminal region of SR-BI, posttranscriptionally, regulates localization and stabi-
lity of SR-BI (Fenske et al. 2009). Inactivation of hepatic PDZK1 significantly
affected plasma HDL metabolism and structure and caused occlusive atherosclero-
sis in double-deficient mice for apoE and PDKZ (Kocher et al. 2008; Yesilaltay
et al. 2009). The detailed mechanism of SR-BI-facilitated selective uptake of the
CE of HDL is not yet clear. It has been suggested that HDL binding to hepatic
SR-BI allows the entry of cholesteryl esters into a channel that is generated by
SR-BI and along which cholesteryl esters move down their concentration gradient
into the cell membrane. During this movement, HDL particles donate their CE to
hepatocytes without the simultaneous uptake and degradation of the whole HDL
particle.
Recent findings reviewed in Meyer et al. (2013) indicated that SR-BI-indepen-
dent cholesterol ester uptake processes may also operate in macrophages. Liver-
specific or whole-body ABCA1 deficiency in mice accelerated HDL catabolism in
plasma without changing the hepatic expression of SR-BI, suggesting that other
membrane proteins, such as those involved in the hepatic F1-ATPase/P2Y13 path-
way (Martinez et al. 2003) (see below for more detail) and CD36 (Brundert
et al. 2011), may be involved in the selective cholesteryl ester uptake. In a large-
scale human study, several CD36 SNPs were strongly associated with HDL choles-
terol levels, thus pointing to a potential role of CD36 in the regulation of human
HDL metabolism (Love-Gregory et al. 2008).
Interactions of HDL with SR-BI in endothelial cells trigger signaling
mechanisms that involve activation of eNOS and release of nitric oxide that causes
vasodilation (Mineo et al. 2003; Yuhanna et al. 2001; Li et al. 2002; Gong
et al. 2003).
Human subjects have been identified with a P297S substitution in SR-BI.
Heterozygote carriers for this mutation had increased HDL levels and decreased
adrenal steroidogenesis and dysfunctional platelets, but did not develop atheroscle-
rosis. HDL derived from these subjects had decreased ability to promote cholesterol
efflux from macrophages (Vergeer et al. 2011). A recent study has shown the
impact of SR-BI SNPs on female fertility (Yates et al. 2011).
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2.7 Role of Ecto-F1-ATPase/P2Y13 Pathway in Hepatic HDL
Clearance
Based on Biacore’s surface plasmon resonance studies of hepatic membranes,
Martinez and his colleagues (Martinez et al. 2003) demonstrated the presence of
a 50 kDa apoA-I binding protein that was identical to the subunit of the β-chain of
ATP synthase (Boyer 1997). The HDL-binding protein was identified as ecto-F1-
ATPase that recognizes apoA-I (Fig. 8d). The multi-subunit ATPase complex
consists of two major domains called F0 and F1 (Boyer 1997). The ecto-F1-ATPase
protein, which resides on cell membranes, hydrolyzes ATP to ADP and phosphate
and can be inhibited by the mitochondrial inhibitor protein IF1 (Cabezon
et al. 2003). It was recently shown that IF1 is present in the serum, and its
concentration correlates negatively with HDL-C levels and the risk for coronary
heart disease (Genoux et al. 2013). Binding of lipid-free apoA-I to the high affinity
side of ecto-F1-ATPase enhances binding of HDL to the low-affinity binding sites.
The apoA-I binding to the ecto-F1-ATPase also increases the production of ADP
that associates with its receptor, purinergic P2Y13 (Jacquet et al. 2005). The ecto-
F1-ATPase/P2Y13-mediated HDL uptake pathway is under careful control.
Adenylate kinase and niacin are important factors that regulate HDL metabolism
and plasma levels via ecto-F1-ATPase (Fabre et al. 2006; Zhang et al. 2008).
Inhibitors of ecto-F1-ATPase or adenylate kinase activity that consume ADP
generated by ecto-F1-ATPase downregulate holo-HDL particle uptake (Genoux
et al. 2013). In vivo studies using a P2Y13-deficient mouse model also indicated that
the P2Y13 ADP receptor may have an important role in HDL-mediated reverse
cholesterol transport (Fabre et al. 2010). It is possible that induction of hepatic ecto-
F1-ATPase/P2Y13 pathway might enhance hepatic HDL endocytosis and turnover
and accelerate cholesterol removal from cholesterol-laden macrophages and other
tissues and cells of the body.
2.8 Transcytosis of apoA-I and HDL by Endothelial Cells
It has been shown that endothelial cells have the ability to bind and transcytose
lipid-free apoA-I in a specific manner. This process depends on ABCA1 and leads
to the generation of a lipidated apoA-I particle that is secreted (Cavelier et al. 2006;
Rohrer et al. 2006). Endothelial cells can also transcytose HDL and this process
required the functions of SR-BI and ABCG1 (Rohrer et al. 2009). ApoA-I mutants
with defective C-terminal apoA-I[Δ(185-243)] and apoA-I[L218A/L219A/V221A/
L222A] had 80 % decreased specific binding and 90 % decreased specific transport
by aortic endothelial cells. Following lipidation of these mutants, the rHDL
particles formed were transported through endothelial cells by an ABCG1- and
SR-BI-dependent process. Amino and combined amino- and carboxy-terminal
apoA-I deletion mutants displayed increased nonspecific binding, but the specific
binding or transport remained absent (Ohnsorg et al. 2011). These data support the
model in which apoA-I is initially lipidated by ABCA1 and subsequently processed
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by ABCA1-independent mechanisms. Transcytosis of apoA-I and HDL may pro-
vide a mechanism for transfer of HDL into the subendothelial space.
2.9 The Role of Cubilin in apoA-I and HDL Catabolism
by the Kidney
It has been shown that in humans, impaired cubilin and amnionless function results
in the Imerslunds-Gra¨sbeck syndrome, which is characterized by intestinal vitamin
B12 malabsorption and proteinuria (Fyfe et al. 2004). Cubilin is a 460 kDa
endocytic receptor which is co-expressed with megalin, a 600 kDa multi-ligand
receptor belonging to the LDL receptor gene family. It is localized in the apical
membranes of epithelial cells in the proximal tubules in the kidney cortex
(Kozyraki 2001). In addition to co-localization of cubilin with megalin, the trans-
membrane protein amnionless is a renal protein that interacts with cubilin and
forms a large cubilin/amnionless complex. In this complex, cubilin plays a role as
a ligand-binding domain, whereas amnionless is essential for subcellular localiza-
tion and endocytosis of cubilin bound to its ligand (Strope et al. 2004; Fyfe
et al. 2004). An important function of cubilin is related to its ability to bind
apoA-I or HDL (Kozyraki et al. 1999). In the kidney, however, HDL particles are
too large to cross the glomerular filtration barrier, and therefore megalin and
cubilin/amnionless protein receptor system is only exposed to filtered lipid-free or
poorly lipidated apoA-I, thereby affecting the overall HDL metabolism (Kozyraki
et al. 1999; Moestrup and Nielsen 2005). In physiological terms, it is considered
that the kidney cortex is a major site of catabolism for lipid-free and poorly
lipidated apoA-I and that this uptake is a concerted action of glomerular filtration,
tubular reabsorption, and intracellular degradation of free apoA-I (Woollett and
Spady 1997). Graversen et al. (2008) analyzed urine samples from patients with
Fanconi syndrome. This is a rare renal proximal tubular reabsorption failure and
also includes dysfunction of cubilin. A high urinary excretion of both apoA-I and
apoA-IV but not apoA-II was evident. This study demonstrated that the human
kidney is a major site for filtered apoA-I and A-IV but not for HDL particles since
urinary excretion of all major lipid classes (phospholipids, triglycerides, choles-
terol, and cholesterol esters) in Fanconi patients was as low as in control subjects
(Graversen et al. 2008). Although the kidney is not considered a central organ in
lipoprotein catabolism, it plays an important role in the degradation of lipid-poor
apoA-I via the cubilin function.
HDL Biogenesis, Remodeling, and Catabolism 87
3 HDL Subclasses
3.1 The Origin and Metabolism of Preb-HDL Subpopulations
Several preβ- and α-HDL subpopulations exist in plasma and are generated as a
consequence of the pathway of biogenesis and remodeling of HDL. These
subpopulations can be separated based on different fractionation procedures
(Fielding and Fielding 1996; Chung et al. 1986; Nichols et al. 1986; Davidson
et al. 1994). The precursor-product relationship between preβ- and α-HDL particles
as well as the precise origin and functions of the preβ-HDL particles is still a matter
of investigation.
It has been reported earlier that preβ-HDL comprises approximately 5 % of total
plasma apoA-I level. It is heterogeneous in size and contains several species of 5–
6 nm in diameter (Fielding and Fielding 1995; Nanjee et al. 2000). The best
characterized species are preβ1 and preβ2 (Fielding and Fielding 1995). The
concentration of preβ1-HDL is increased in large lymph vessels (Asztalos
et al. 1993) and in aortic intima (Heideman and Hoff 1982).
Preβ-HDL particles can be formed by two different routes. The first is de novo
synthesis by the HDL biogenesis pathway (Fig. 8a). The second is generation of
preβ-HDL particles from α-HDL particles by reactions catalyzed by CETP, PLTP,
HL, EL, and apoM discussed earlier (Barrans et al. 1994; Maugeais et al. 2003c;
Arai et al. 2000; Huuskonen et al. 2001; Christoffersen et al. 2008b) (Fig. 8a–c).
Cell culture studies showed that lipid-free apoA-I added to a culture medium of
CHO cells can recruit phospholipids and cholesterol, initially to form small 73 A˚
particles, and subsequently larger apoA-I-containing particles by the action of
LCAT that have a precursor-product relationship (Forte et al. 1993, 1995).
Subsequent studies showed that a large proportion of apoA-I is secreted from
HepG-2, CaCo-2, or apoA-I expressing CHO cells in lipid-free monomeric form,
with a Stokes radius of 2.6 nm and preα electrophoretic mobility that is unable to
promote efflux of phospholipids and cholesterol. It was suggested that in a reaction
dependent on ABCA1, the 2.6 nm form was converted into a 3.6 nm monomeric
apoA-I form with preβ electrophoretic mobility that was able to promote efflux of
phospholipids and cholesterol from cells and thus increase its size (Chau
et al. 2006). Expression of apoM in cells transfected with ABCA1 can also increase
the size of preβ-HDL (Mulya et al. 2010). Other studies have shown that some types
of preβ-HDL particles can be formed independently of apoA-I/ABCA1 interactions
in the plasma of humans with Tangier disease and the plasma of apoA-I-deficient
mice expressing mutant apoA-I forms (Chroni et al. 2007; Fotakis et al. 2013a;
Asztalos et al. 2001). Furthermore, inhibition of ABCA1 in HepG2 cells and
macrophage cultures by glyburide inhibited the formation of α-HDL particles but
did not affect the formation of preβ-HDL particles (Krimbou et al. 2005).
The presence of increased concentrations of preβ1-HDL in the vascular bed
suggests that these particles may be generated locally by gradual lipidation of lipid-
poor apoA-I (Heideman and Hoff 1982; Smith et al. 1984). Preβ-HDL particles are
typically lipid-poor and therefore they are efficient in promoting ABCA1-mediated
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cholesterol efflux. The ABCA1/preβ1-HDL interaction provides phospholipids and
cholesterol and thereby converts the preβ-HDL to α-HDL-migrating particles.
These particles may be enlarged further by recruitment of phospholipids and
cholesterol from cell membranes (Fielding and Fielding 2007). In addition, esterifi-
cation of the cholesterol of preβ1-HDL by LCAT contributes to their gradual
conversion into spherical HDL without prior formation of discoidal HDL particles
(Nakamura et al. 2004b; Fielding and Fielding 2007).
3.2 Complexity of HDL
Genome-wide association studies demonstrated that new genes and the
corresponding proteins affect plasma HDL levels by unknown mechanisms
(Holleboom et al. 2008; Kathiresan et al. 2008b, 2009; Sabatti et al. 2009;
Aulchenko et al. 2009; Teslovich et al. 2010; Richards et al. 2009; Willer
et al. 2008; Chasman et al. 2009; Waterworth et al. 2010; Laurila et al. 2013). In
parallel, proteomic analysis showed that a large number of plasma proteins can
associate with HDL and this may affect the HDL structure and functions (Fig. 9)
(Gordon et al. 2010). The proteins associated with HDL can be classified in six
major categories and include proteins involved in lipid, lipoprotein, and HDL
biogenesis and metabolism, acute phase proteins, protease inhibitors, complement
regulatory proteins, and a few others (albumin, fibrinogen a chain platelet basic
protein) (Vaisar et al. 2007; Davidson et al. 2009b). Differences were observed in
Fig. 9 Schematic representation of proteins associated with HDL and factors that may affect
HDL levels and functions
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the proteomic composition of HDL subpopulations derived from HDL particles of
different sizes (Davidson et al. 2009a). Furthermore the HDL proteome could be
altered by pharmacological treatments (Green et al. 2008).
The modulation of the concentration of various proteins associated with HDL
has been studied in more detail under conditions of infection, inflammation, or
tissue injury. Under these conditions, acute phase response is triggered that causes
huge alterations in hepatic protein synthesis in response to cytokines that alter HDL
protein composition (Rohrer et al. 2004; Shah et al. 2013). These changes include
the abrupt increase in serum amyloid A, apoJ, and secretory non-pancreatic phos-
pholipase A2 and a decrease in apoA-I, paraoxonase-1, LCAT, and PLTP. These
changes affect the capacity of HDL to promote cellular cholesterol efflux as well as
other HDL functions (Rohrer et al. 2004; Shah et al. 2013).
In addition to the variety of proteins, a variety of lipids are also carried by HDL,
and some of them are or can be transformed to potent bioactive molecules (Vickers
and Remaley 2014). Furthermore, HDL carries and transports fat soluble vitamins,
steroid hormones, carotenoids, as well as numerous more polar metabolites such as
heneicosanoic acid, pentitol, and oxalic acid which were found to be significantly
correlated with insulin resistance (Vickers and Remaley 2014). Finally, it has been
reported that HDL also transports small RNAs, including microRNAs, tRNA-
derived RNA fragments, and RNase P-derived RNA fragments (Vickers
et al. 2011). How all this protein decoration affects HDL metabolism and HDL
particle function remain to be studied.
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